<collection><source>PMC</source><date>20201214</date><key>pmc.key</key><document><id>37353</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_doi">10.1186/1471-2172-2-6</infon><infon key="article-id_pmc">37353</infon><infon key="article-id_pmid">11504561</infon><infon key="article-id_publisher-id">1471-2172-2-6</infon><infon key="fpage">6</infon><infon key="journal-title">BMC Immunology</infon><infon key="lpage">6</infon><infon key="name_0">surname:Nunez;given-names:Rafael</infon><infon key="name_1">surname:Filgueira;given-names:Luis</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">2</infon><infon key="year">2001</infon><offset>0</offset><text>Flow cytometric assessment of the reactivity of a panel of monoclonal antibodies (mAb) against two populations of human dendritic cells (DC)</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>141</offset><text>What is the background on this?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>152</offset><text>We have been unable to identify the antigens that affect human DC due to the lack of appropriate reagents. Therefore, we evaluated the expression of DC antigenic markers in three models: Molecules and Langerhans cells, and flow cytometry to determine their response to various anti-DC antibody detection strategies.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>602</offset><text>What are the outcomes?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>610</offset><text>On day 7, it was discovered that mAb BG6, HP-F1, BU10, RFD-1, CMFR-4, and CF4 reacted with Mo-DC at a rate of approximately 50%. In contrast, 7H5, ZM3.8, MMR1.16, MRF-56, CDlb/c, 55K-2, MPRM1.13, MRB190.BB3 and L25 reacquired &gt;50% of Mo&#8211;DC. Similarly, Abr 5's MB20% of the MoD-C1.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1227</offset><text>At 14 mAb, fourteen remained positive (&gt;50%) and five 20&#8211;50% of the Mo-DC), while in 19 MBAb they were negative (7%) and nineteen mmAbAbored &gt;48% of Mo-LC, with BG6 showing negligibility.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1427</offset><text>On day 21 and 28, every mAb antibody reagent showed a significant amount of Mo-DC in it, with all three exhibiting MFI with Mo&#8211;DC. Nineteen mmAb exhibited significant amounts of MO-LC, while RFD-7 did not.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1596</offset><text>Remarkable conclusions</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1608</offset><text>Immunophageal assays used revealed variations in the reactivity of the immunophenotyping as well as differences between the two DC populations at different times, suggesting subcellular subgroups within the Mo-DC and Mo&#8211;LC.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1839</offset><text>The majority of the world's population is susceptible to acquired immunodeficiency syndrome (AIDS) (1,2). This condition is caused by a mutation in the B cell receptor (BCR) gene. The majority of people with acquired immunodeficiency syndrome (AIDS) are found in low income countries, such as Africa, the Middle East and Asia. The vast majority of the cases of acquired immunodeficiency syndrome (AIDS) are due to the virus.

The majority of people with acquired immunodeficiency syndrome (AIDS) have a mutation in the B cell receptor (BCR) gene. The majority of people with acquired immunodeficiency syndrome (AIDS) have a mutation in the B cell receptor</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1850</offset><text>The afferent branch of the immune response is largely composed of bone marrow derived cells, known as dendritic cells (DC), which constitute 2% of all cells in the human epidermis.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2885</offset><text>Recent, effective efforts have led to the production of DC from PBMC-derived monocytes or from CD34 blood precursors through GM-CSF and IL-4, as well as MG-CSB and TNF.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3188</offset><text>Despite the fact that blood precursors have yielded DC, the identification of surface markers on human DC has been challenging and elusive due to the lack of appropriate reagents with high specificity. Nevertheless, some molecules that have been recently clone-free and sequenced (e.g. CD83, DEC-205) have also been found to be strongly associated with DC. Additionally, there is a growing need for clustering and nomenclature for such DC associated molecules, as well as to clarify and define the existence of DC subsets of different populations.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>4350</offset><text>Results and Discussion</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>4373</offset><text>Flow cytometric assessments of monoclonal antibodies (mAb) reactivity against dendritic cells (DC) was undertaken by measurement of the % of reactivity (Figure 1,2,3,4) and mean fluorescent intensity (MFI) of two populations of DC at 7, 14, 21 and 28 days (Table 1). At day 7 (Figure 1), the flow cytometry evaluation showed that, antibodies 70011 (BG6), 70194 (HP-F1 (CD85i)), 70293 (BU10), 70511 (RFD-1) and 70375 (CMRF-44) recognized less than 20 % of Mo-DC. In contrast, 70345 (7H5 (CD85a)), 70358 (ZM3.8 (CD85j)), 70807 (CDlb/c), 70806 (55K-2 fascin), 70776 (MMR1.16 (CD206)), 70767 (MMR190.BB3 (CD206)) and 70772 (L25) reacted with more than 50% of Mo-DC. Moreover, 70345 (7H5 (CD85a)), 70358 (ZM3.8 (CD85j)), 70376 (CMRF-56), 70807 (CDlb/c), 70806 (55K-2 fascin), 70776 (MMR1.16 (CD206)), 70767 (MMR190.BB3 (CD206)) and 70772 (L25) also showed increase MFI reactivity against Mo-DC (Table 1).</text></passage><passage><infon key="file">1471-2172-2-6-1.jpg</infon><infon key="id">F1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>5273</offset><text>Percentage of positive cells detected by mAb against Mo-DC and LC-DC after 7 days of culture</text></passage><passage><infon key="file">1471-2172-2-6-2.jpg</infon><infon key="id">F2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>5366</offset><text>Percentage of positive cells detected by mAb against Mo-DC and LC-DC after 14 days of culture</text></passage><passage><infon key="file">1471-2172-2-6-3.jpg</infon><infon key="id">F3</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>5460</offset><text>Percentage of positive cells detected by mAb against Mo-DC and LC-DC after 21 days of culture</text></passage><passage><infon key="file">1471-2172-2-6-4.jpg</infon><infon key="id">F4</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>5554</offset><text>Percentage of positive cells detected by mAb against Mo-DC and LC-DC after 28 days of culture</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>5648</offset><text>MFI of mAb reactivity against HDC</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="center" colspan="2"&gt;Day 7&lt;/td&gt;&lt;td align="center" colspan="2"&gt;Day 14&lt;/td&gt;&lt;td align="center" colspan="2"&gt;Day 21&lt;/td&gt;&lt;td align="center" colspan="2"&gt;Day 28&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;hr/&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;hr/&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;hr/&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;hr/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="center"&gt;Mo-DC&lt;/td&gt;&lt;td align="center"&gt;Mo-LC&lt;/td&gt;&lt;td align="center"&gt;Mo-DC&lt;/td&gt;&lt;td align="center"&gt;Mo-LC&lt;/td&gt;&lt;td align="center"&gt;Mo-DC&lt;/td&gt;&lt;td align="center"&gt;Mo-LC&lt;/td&gt;&lt;td align="center"&gt;Mo-DC&lt;/td&gt;&lt;td align="center"&gt;Mo-LC&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;BG6&lt;/td&gt;&lt;td align="center"&gt;72&lt;/td&gt;&lt;td align="center"&gt;57&lt;/td&gt;&lt;td align="center"&gt;81&lt;/td&gt;&lt;td align="center"&gt;149&lt;/td&gt;&lt;td align="center"&gt;637&lt;/td&gt;&lt;td align="center"&gt;256&lt;/td&gt;&lt;td align="center"&gt;644&lt;/td&gt;&lt;td align="center"&gt;1100&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;HP-F1&lt;/td&gt;&lt;td align="center"&gt;48&lt;/td&gt;&lt;td align="center"&gt;274&lt;/td&gt;&lt;td align="center"&gt;160&lt;/td&gt;&lt;td align="center"&gt;199&lt;/td&gt;&lt;td align="center"&gt;717&lt;/td&gt;&lt;td align="center"&gt;310&lt;/td&gt;&lt;td align="center"&gt;615&lt;/td&gt;&lt;td align="center"&gt;1252&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;ZM3.8&lt;/td&gt;&lt;td align="center"&gt;180&lt;/td&gt;&lt;td align="center"&gt;155&lt;/td&gt;&lt;td align="center"&gt;332&lt;/td&gt;&lt;td align="center"&gt;305&lt;/td&gt;&lt;td align="center"&gt;515&lt;/td&gt;&lt;td align="center"&gt;226&lt;/td&gt;&lt;td align="center"&gt;747&lt;/td&gt;&lt;td align="center"&gt;1025&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;7H5&lt;/td&gt;&lt;td align="center"&gt;176&lt;/td&gt;&lt;td align="center"&gt;153&lt;/td&gt;&lt;td align="center"&gt;366&lt;/td&gt;&lt;td align="center"&gt;402&lt;/td&gt;&lt;td align="center"&gt;387&lt;/td&gt;&lt;td align="center"&gt;221&lt;/td&gt;&lt;td align="center"&gt;382&lt;/td&gt;&lt;td align="center"&gt;859&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;42D1&lt;/td&gt;&lt;td align="center"&gt;138&lt;/td&gt;&lt;td align="center"&gt;129&lt;/td&gt;&lt;td align="center"&gt;175&lt;/td&gt;&lt;td align="center"&gt;157&lt;/td&gt;&lt;td align="center"&gt;278&lt;/td&gt;&lt;td align="center"&gt;150&lt;/td&gt;&lt;td align="center"&gt;291&lt;/td&gt;&lt;td align="center"&gt;562&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;BU10&lt;/td&gt;&lt;td align="center"&gt;50&lt;/td&gt;&lt;td align="center"&gt;97&lt;/td&gt;&lt;td align="center"&gt;171&lt;/td&gt;&lt;td align="center"&gt;172&lt;/td&gt;&lt;td align="center"&gt;296&lt;/td&gt;&lt;td align="center"&gt;161&lt;/td&gt;&lt;td align="center"&gt;392&lt;/td&gt;&lt;td align="center"&gt;320&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;DCGM-4&lt;/td&gt;&lt;td align="center"&gt;115&lt;/td&gt;&lt;td align="center"&gt;125&lt;/td&gt;&lt;td align="center"&gt;177&lt;/td&gt;&lt;td align="center"&gt;193&lt;/td&gt;&lt;td align="center"&gt;570&lt;/td&gt;&lt;td align="center"&gt;288&lt;/td&gt;&lt;td align="center"&gt;608&lt;/td&gt;&lt;td align="center"&gt;1317&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;DC-LAMP&lt;/td&gt;&lt;td align="center"&gt;148&lt;/td&gt;&lt;td align="center"&gt;126&lt;/td&gt;&lt;td align="center"&gt;296&lt;/td&gt;&lt;td align="center"&gt;205&lt;/td&gt;&lt;td align="center"&gt;601&lt;/td&gt;&lt;td align="center"&gt;252&lt;/td&gt;&lt;td align="center"&gt;567&lt;/td&gt;&lt;td align="center"&gt;712&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;TPD153&lt;/td&gt;&lt;td align="center"&gt;124&lt;/td&gt;&lt;td align="center"&gt;141&lt;/td&gt;&lt;td align="center"&gt;189&lt;/td&gt;&lt;td align="center"&gt;198&lt;/td&gt;&lt;td align="center"&gt;482&lt;/td&gt;&lt;td align="center"&gt;510&lt;/td&gt;&lt;td align="center"&gt;657&lt;/td&gt;&lt;td align="center"&gt;808&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;RFD-1&lt;/td&gt;&lt;td align="center"&gt;102&lt;/td&gt;&lt;td align="center"&gt;113&lt;/td&gt;&lt;td align="center"&gt;161&lt;/td&gt;&lt;td align="center"&gt;175&lt;/td&gt;&lt;td align="center"&gt;374&lt;/td&gt;&lt;td align="center"&gt;193&lt;/td&gt;&lt;td align="center"&gt;376&lt;/td&gt;&lt;td align="center"&gt;712&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;RFD-7&lt;/td&gt;&lt;td align="center"&gt;150&lt;/td&gt;&lt;td align="center"&gt;167&lt;/td&gt;&lt;td align="center"&gt;209&lt;/td&gt;&lt;td align="center"&gt;621&lt;/td&gt;&lt;td align="center"&gt;165&lt;/td&gt;&lt;td align="center"&gt;114&lt;/td&gt;&lt;td align="center"&gt;168&lt;/td&gt;&lt;td align="center"&gt;158&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;CMRF-44&lt;/td&gt;&lt;td align="center"&gt;79&lt;/td&gt;&lt;td align="center"&gt;111&lt;/td&gt;&lt;td align="center"&gt;160&lt;/td&gt;&lt;td align="center"&gt;185&lt;/td&gt;&lt;td align="center"&gt;348&lt;/td&gt;&lt;td align="center"&gt;152&lt;/td&gt;&lt;td align="center"&gt;339&lt;/td&gt;&lt;td align="center"&gt;115&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;CMRF-56&lt;/td&gt;&lt;td align="center"&gt;193&lt;/td&gt;&lt;td align="center"&gt;200&lt;/td&gt;&lt;td align="center"&gt;209&lt;/td&gt;&lt;td align="center"&gt;203&lt;/td&gt;&lt;td align="center"&gt;977&lt;/td&gt;&lt;td align="center"&gt;421&lt;/td&gt;&lt;td align="center"&gt;974&lt;/td&gt;&lt;td align="center"&gt;2232&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;L25&lt;/td&gt;&lt;td align="center"&gt;334&lt;/td&gt;&lt;td align="center"&gt;353&lt;/td&gt;&lt;td align="center"&gt;279&lt;/td&gt;&lt;td align="center"&gt;336&lt;/td&gt;&lt;td align="center"&gt;866&lt;/td&gt;&lt;td align="center"&gt;890&lt;/td&gt;&lt;td align="center"&gt;792&lt;/td&gt;&lt;td align="center"&gt;1430&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;55K-2&lt;/td&gt;&lt;td align="center"&gt;237&lt;/td&gt;&lt;td align="center"&gt;228&lt;/td&gt;&lt;td align="center"&gt;373&lt;/td&gt;&lt;td align="center"&gt;215&lt;/td&gt;&lt;td align="center"&gt;1029&lt;/td&gt;&lt;td align="center"&gt;526&lt;/td&gt;&lt;td align="center"&gt;1044&lt;/td&gt;&lt;td align="center"&gt;2020&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;CD1b/c&lt;/td&gt;&lt;td align="center"&gt;789&lt;/td&gt;&lt;td align="center"&gt;515&lt;/td&gt;&lt;td align="center"&gt;392&lt;/td&gt;&lt;td align="center"&gt;398&lt;/td&gt;&lt;td align="center"&gt;408&lt;/td&gt;&lt;td align="center"&gt;234&lt;/td&gt;&lt;td align="center"&gt;384&lt;/td&gt;&lt;td align="center"&gt;654&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;DEC-205&lt;/td&gt;&lt;td align="center"&gt;162&lt;/td&gt;&lt;td align="center"&gt;127&lt;/td&gt;&lt;td align="center"&gt;227&lt;/td&gt;&lt;td align="center"&gt;171&lt;/td&gt;&lt;td align="center"&gt;548&lt;/td&gt;&lt;td align="center"&gt;281&lt;/td&gt;&lt;td align="center"&gt;430&lt;/td&gt;&lt;td align="center"&gt;915&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;MMR1.16&lt;/td&gt;&lt;td align="center"&gt;194&lt;/td&gt;&lt;td align="center"&gt;265&lt;/td&gt;&lt;td align="center"&gt;319&lt;/td&gt;&lt;td align="center"&gt;281&lt;/td&gt;&lt;td align="center"&gt;570&lt;/td&gt;&lt;td align="center"&gt;272&lt;/td&gt;&lt;td align="center"&gt;656&lt;/td&gt;&lt;td align="center"&gt;1147&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;MMR190.BB3&lt;/td&gt;&lt;td align="center"&gt;716&lt;/td&gt;&lt;td align="center"&gt;570&lt;/td&gt;&lt;td align="center"&gt;702&lt;/td&gt;&lt;td align="center"&gt;778&lt;/td&gt;&lt;td align="center"&gt;881&lt;/td&gt;&lt;td align="center"&gt;447&lt;/td&gt;&lt;td align="center"&gt;1019&lt;/td&gt;&lt;td align="center"&gt;1917&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;MR15-2&lt;/td&gt;&lt;td align="center"&gt;151&lt;/td&gt;&lt;td align="center"&gt;278&lt;/td&gt;&lt;td align="center"&gt;547&lt;/td&gt;&lt;td align="center"&gt;520&lt;/td&gt;&lt;td align="center"&gt;721&lt;/td&gt;&lt;td align="center"&gt;476&lt;/td&gt;&lt;td align="center"&gt;588&lt;/td&gt;&lt;td align="center"&gt;817&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;CMRF-75&lt;/td&gt;&lt;td align="center"&gt;155&lt;/td&gt;&lt;td align="center"&gt;209&lt;/td&gt;&lt;td align="center"&gt;266&lt;/td&gt;&lt;td align="center"&gt;234&lt;/td&gt;&lt;td align="center"&gt;432&lt;/td&gt;&lt;td align="center"&gt;186&lt;/td&gt;&lt;td align="center"&gt;403&lt;/td&gt;&lt;td align="center"&gt;507&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;CMRF-82&lt;/td&gt;&lt;td align="center"&gt;153&lt;/td&gt;&lt;td align="center"&gt;182&lt;/td&gt;&lt;td align="center"&gt;340&lt;/td&gt;&lt;td align="center"&gt;232&lt;/td&gt;&lt;td align="center"&gt;760&lt;/td&gt;&lt;td align="center"&gt;357&lt;/td&gt;&lt;td align="center"&gt;946&lt;/td&gt;&lt;td align="center"&gt;1420&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;CD1a&lt;/td&gt;&lt;td align="center"&gt;801&lt;/td&gt;&lt;td align="center"&gt;493&lt;/td&gt;&lt;td align="center"&gt;423&lt;/td&gt;&lt;td align="center"&gt;603&lt;/td&gt;&lt;td align="center"&gt;443&lt;/td&gt;&lt;td align="center"&gt;232&lt;/td&gt;&lt;td align="center"&gt;354&lt;/td&gt;&lt;td align="center"&gt;434&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;2nd Ab&lt;/td&gt;&lt;td align="center"&gt;80&lt;/td&gt;&lt;td align="center"&gt;106&lt;/td&gt;&lt;td align="center"&gt;121&lt;/td&gt;&lt;td align="center"&gt;165&lt;/td&gt;&lt;td align="center"&gt;97&lt;/td&gt;&lt;td align="center"&gt;81&lt;/td&gt;&lt;td align="center"&gt;85&lt;/td&gt;&lt;td align="center"&gt;105&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>5682</offset><text>	Day 7	Day 14	Day 21	Day 28	 						 		Mo-DC	Mo-LC	Mo-DC	Mo-LC	Mo-DC	Mo-LC	Mo-DC	Mo-LC	 	BG6	72	57	81	149	637	256	644	1100	 	HP-F1	48	274	160	199	717	310	615	1252	 	ZM3.8	180	155	332	305	515	226	747	1025	 	7H5	176	153	366	402	387	221	382	859	 	42D1	138	129	175	157	278	150	291	562	 	BU10	50	97	171	172	296	161	392	320	 	DCGM-4	115	125	177	193	570	288	608	1317	 	DC-LAMP	148	126	296	205	601	252	567	712	 	TPD153	124	141	189	198	482	510	657	808	 	RFD-1	102	113	161	175	374	193	376	712	 	RFD-7	150	167	209	621	165	114	168	158	 	CMRF-44	79	111	160	185	348	152	339	115	 	CMRF-56	193	200	209	203	977	421	974	2232	 	L25	334	353	279	336	866	890	792	1430	 	55K-2	237	228	373	215	1029	526	1044	2020	 	CD1b/c	789	515	392	398	408	234	384	654	 	DEC-205	162	127	227	171	548	281	430	915	 	MMR1.16	194	265	319	281	570	272	656	1147	 	MMR190.BB3	716	570	702	778	881	447	1019	1917	 	MR15-2	151	278	547	520	721	476	588	817	 	CMRF-75	155	209	266	234	432	186	403	507	 	CMRF-82	153	182	340	232	760	357	946	1420	 	CD1a	801	493	423	603	443	232	354	434	 	2nd Ab	80	106	121	165	97	81	85	105	 	</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>6748</offset><text>The mAb 70011 (BG6), 70293 (BU10) and 70375 (CMRF-44) recognized less than 20% Mo-LC while 70511 reacted with only 21% of the cells. In contrast, 70194 (HP-F1 (CD85i)) showed that 87% of Mo-LCs were positive. Also, 70345 (7H5 (CD85a)), 70358 (ZM3.8 (CD85j)), 70512 (RFD-7), 70802 (MR15-2 (CD205)), 70807 (CDlb/c), 70806 (55K-2 fascin), 70776 (MMR1.16 (CD206)), 70767 (MMR190.BB3 (CD206)), 70772 (L25) reacted with more than 50% of Mo-LC. The increase in % of positive cells was also paralleled by MFI increases (Table 1).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>7270</offset><text>At day 14 (Figure 2), 14 mAb recognized more than 50% of the Mo-DC, while 70427 (DCGM-4 (CD207)), 70451 (TPD153), 70511 (RFD-1), 70512 (RFD-7) and 70375 (CMRF-44) recognized between 20 and 50% of Mo-DC. 70011 (BG6) reacted with 7% of the Mo-DC. The reactivity of 70011 (BG6) against Mo-LC was indistinguishable from the background while the other nineteen mAb recognized more than 48% of Mo-LC. At day 21 and 28, all the mAb reacted with more than 20% of Mo-DC (Figure 3 and 4). Also, the mAb yielded a significant MFI with Mo-DC (Table 1). In addition, nineteen mAb yielded significant MFI with Mo-LC whilst only 70512 (RFD-7) did not. (Table 1) At day 21 (Figure 3), seventeen mAb reacted with more than 50% of the Mo-DC, only 70346 (42D1 (CD85f)), 70511 (RFD-1) and 70512 (RFD-7) were below 50%. In contrast, only seven mAb reacted with more than 50% Mo-LC but only 70512 (RFD-7) reacted with less than 20% Mo-LC. At day 28 (Figure 4), sixteen mAb reacted with more than 50% Mo-DC. The mAb 70346 (42D1 (CD85f)), 70511 (RFD-1), 70512 (RFD-7) and 70808 (DEC-205 (CD205)) were below 50% while 70375 (CMRF-44) reacted with less than 20% of Mo-LC. Seventeen mAb reacted with more than 50% of Mo-LC.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>8467</offset><text>The simultaneous evaluation on Mo-DC and Mo-LC of FSC (flow cytometric assessment of size) and mAb reactivity at four time points demonstrated the presence of significant variability within the Mo-DC and Mo-LC populations (Figure 5). At day seven, there was several mAb that showed strong reactivity and can be grouped together (Figure 5 panel C mAb-MMR.190.BB3 and panel E mAb-L25). In addition there was another group of mAb with an intermediate level of reactivity that can be grouped together (Figure 5 panel D mAb-7H5 and panel F mAb-ZM-38). However, some mAb showed no reactivity at day seventh (Figure 5 panel A mAb-BG6) compared with the negative control (Figure 5 panel B-Second Ab). In addition, variations in the reactivity of the mAb at diverse time points were found. Moreover, at day seven it was found that mAb HP-F1 was negative for Mo-DC and positive for Mo-LC, thus discriminating Mo-DC from Mo-LC. Overall, this set of results demonstrates the existence of antigenic differences between Mo-DC and Mo-LC, even though there was only a single difference in the cytokine mixture utilized. Moreover, within the panel analyzed, it was found that at day 7, there is a mAb that showed reactivity only against Mo-DC with high FSC (mAb-TPD153) or against a fraction of Mo-DC (mAb-DC-LAMP, mAb-55K-2). These results point toward the existence of subsets within the Mo-DC and Mo-LC populations.</text></passage><passage><infon key="file">1471-2172-2-6-5.jpg</infon><infon key="id">F5</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>9869</offset><text>Density plots of Mo-DC and LC-DC reactivity to five mAb after 7 days of culture. Density plot representation of FSC and mAb reactivity at day seventh has been utilized to demonstrate the presence of significant variability within the Mo-DC and Mo-LC populations. Panel A displayed mAb-BG6 in comparison with the negative control that is showed in panel B-Second Ab. Panel C showed mAb-MMR190.BB3. Panel D displayed mAb-7H5. Panel E showed mAb-L25. Panel F displayed mAb-ZM-38.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>10346</offset><text>Of note, the studies on the reactivity of two set of mAb (mannose receptor and immunoglobulin-like transcript molecules) raised very interesting considerations about the role of these antigens in the functionality of DC.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>10567</offset><text>This study showed that DC expressed significant amounts of two lectin-type receptors: the mannose receptor (MMR) detected by the mAbs MR 15-2 (CD206), MMR1.16 (CD206), and MMR190.BB3 (CD206?), and the antigen DEC-205 detected by the mAbs DEC-205 (CD205) and MMRI-4 (CD205). Both molecules belong to a family of transmembrane C-type lectins. Both molecules have (i) a cysteine-rich domain, (ii) a fibronectin type II domain, (iii) multiple C-type carbohydrate recognition-like domains, (iv) a transmembrane domain and (v) a short cytoplasmic tail. Both molecules the MMR and DEC-205, have been implicated in the uptake of carbohydrate-conjugated antigens by DC. MMR has been found on the cell surface of macrophages and its carbohydrate recognition domains mediate the endocytosis of (i) glycoconjugates containing mannose, (ii) fucose, (iii) acetylglucosamine, (iv) glucose residues, (v) microorganisms expressing mannose or acetylglucosamine on the surface. Notably, all these terminal sugars are neither common membrane components of mammalian cells nor common components of serum proteins. Therefore, it is feasible to consider that this two lectin-type receptors: the mannose receptor (MMR) and DEC-205 may be involved in the discrimination between self and non-self antigens as well and could contribute to enhance the capability of dendritic cells to generate primary T cell responses against infectious agents and soluble antigens that carry these types of carbohydrates.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12046</offset><text>In addition, this study provides the first comparison of the distribution of the MMR and DEC-205 on two human blood derived DC, Mo-LC and Mo-DC.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12191</offset><text>A panel of mAb that recognize several immunoglobulin-like transcript molecules (ILT) was also evaluated in this study. The mAb HP-F1 (CD85i) identified ILT2, ZM3.8 (CD85j) recognized ILT3, 42D1 (CD85f) identified ILT4 and 7H5 (CD85a) recognized ILT5. One significant feature of the ILTs molecules is their capability to bind MHC class I molecules. Furthermore, the molecules ILT2, ILT3, ILT4, and ILT5 have been considered to play a role as inhibitory receptors because they carry the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the intracytoplasmic tail. Because of (i) the binding capability of ILT2-5 to MHC class I molecules, (ii) the presence of inhibitory motifs within the cytoplasmic tail of ILT2-5 and (iii) the identification of ILT2-5, within diverse populations of dendritic cells, is likely that the ILT molecules identified on DC may not only perform a key role as the receptor for the "missing self but also could contribute to control the initial steps of activation of the immune response; Thus, this would tune up the fine balance between the activation signals provided by the simultaneous cross-linking of MHC class I or II and co-stimulatory molecules during the interaction between DC with T cells and the inhibitory signals mediated through the whole variety of ILTs molecules carrying ITIM motifs. Further functional studies of the role of ILTs on DC will provide insight toward the understanding of these mechanisms and its role in the regulation of the DC function.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>13696</offset><text>Remarkable conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>13708</offset><text>By using the immunophenotyping assays discussed in this report, we were able to identify differences between Mo-DC and Mo&#8211;LC populations in human DC, subsets of these populations, the expression of antigens at different times on DC (ii) and kinetics, and specific markers for certain subpopulations.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>14069</offset><text>Material and methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>14090</offset><text>Monoclonal antibodies (mAb)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>14118</offset><text>A panel of mAb with potential reactivity against DC was evaluated by setting up a flow cytometry approach. The panel of antibodies was kindly provided by Dr. D. Hart. Antibodies are listed in Table 1 {CDIa, CDlb/c, BG6, HP-F1 (CD85i), BU10, RFD-1, CMRF-44, 7H5 (CD85a), ZM3.8 (CD85j), 55K-2 (fascin), MMR1.16, MMR190.BB3 (CD206), L25, CMRF-56, RFD-7, MR15-2 (CD205), DCGM-4 (CD207), TPD153, 42D1 (CD85f), DEC-205 (CD205), MMRI-4 (CD205), DC-LAMP (CD208), AZN-D1 (CD209), AZN-D2 (CD209), CMRF-75, CMRF-82, CD11c, CD80, CD86 and HLA-DR}. The panel of antibodies that was utilized in the Dendritic cell section of the 7th workshop for HLDA is listed in table 2.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>14777</offset><text>List of monoclonal antibodies</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align="left"&gt;Sample&lt;/td&gt;&lt;td align="left"&gt;Panel number&lt;/td&gt;&lt;td align="left"&gt;Monoclonal antibody (CD&lt;sup&gt;*&lt;/sup&gt;)&lt;/td&gt;&lt;td align="left"&gt;Reference&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;1&lt;/td&gt;&lt;td align="left"&gt;70011&lt;/td&gt;&lt;td align="left"&gt;BG6&lt;/td&gt;&lt;td align="left"&gt;12&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;2&lt;/td&gt;&lt;td align="left"&gt;70194&lt;/td&gt;&lt;td align="left"&gt;HP-Fl(CD85i)ILT2&lt;/td&gt;&lt;td align="left"&gt;13&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;3&lt;/td&gt;&lt;td align="left"&gt;70293&lt;/td&gt;&lt;td align="left"&gt;BU10&lt;/td&gt;&lt;td align="left"&gt;14&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;4&lt;/td&gt;&lt;td align="left"&gt;70345&lt;/td&gt;&lt;td align="left"&gt;7H5 (CD85a) ILT5&lt;/td&gt;&lt;td align="left"&gt;15&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;5&lt;/td&gt;&lt;td align="left"&gt;70346&lt;/td&gt;&lt;td align="left"&gt;42D1 (CD85f)ILT4&lt;/td&gt;&lt;td align="left"&gt;16&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;6&lt;/td&gt;&lt;td align="left"&gt;70358&lt;/td&gt;&lt;td align="left"&gt;ZM3.8 (CD85j) ILT3&lt;/td&gt;&lt;td align="left"&gt;17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;7&lt;/td&gt;&lt;td align="left"&gt;70427&lt;/td&gt;&lt;td align="left"&gt;DCGM-4 (CD207) Langerin&lt;/td&gt;&lt;td align="left"&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;8&lt;/td&gt;&lt;td align="left"&gt;70435&lt;/td&gt;&lt;td align="left"&gt;DC-LAMP (CD208)&lt;/td&gt;&lt;td align="left"&gt;19&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;9&lt;/td&gt;&lt;td align="left"&gt;70451&lt;/td&gt;&lt;td align="left"&gt;TPD153&lt;/td&gt;&lt;td align="left"&gt;20&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;10&lt;/td&gt;&lt;td align="left"&gt;70511&lt;/td&gt;&lt;td align="left"&gt;RFD-1&lt;/td&gt;&lt;td align="left"&gt;21&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;11&lt;/td&gt;&lt;td align="left"&gt;70512&lt;/td&gt;&lt;td align="left"&gt;RFD-7&lt;/td&gt;&lt;td align="left"&gt;22&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;12&lt;/td&gt;&lt;td align="left"&gt;70375&lt;/td&gt;&lt;td align="left"&gt;CMRF-44&lt;/td&gt;&lt;td align="left"&gt;7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;13&lt;/td&gt;&lt;td align="left"&gt;70376&lt;/td&gt;&lt;td align="left"&gt;CMRF-56&lt;/td&gt;&lt;td align="left"&gt;23&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;14&lt;/td&gt;&lt;td align="left"&gt;70802&lt;/td&gt;&lt;td align="left"&gt;MR15-2 (CD206)&lt;/td&gt;&lt;td align="left"&gt;24&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;15&lt;/td&gt;&lt;td align="left"&gt;70808&lt;/td&gt;&lt;td align="left"&gt;DEC-205 (CD205)&lt;/td&gt;&lt;td align="left"&gt;6,12,25&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;16&lt;/td&gt;&lt;td align="left"&gt;70807&lt;/td&gt;&lt;td align="left"&gt;CDlb/c&lt;/td&gt;&lt;td align="left"&gt;31&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;17&lt;/td&gt;&lt;td align="left"&gt;70806&lt;/td&gt;&lt;td align="left"&gt;55K-2 fascin&lt;/td&gt;&lt;td align="left"&gt;26&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;18&lt;/td&gt;&lt;td align="left"&gt;70776&lt;/td&gt;&lt;td align="left"&gt;MMR1.16 (CD206)&lt;/td&gt;&lt;td align="left"&gt;27&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;19&lt;/td&gt;&lt;td align="left"&gt;70767&lt;/td&gt;&lt;td align="left"&gt;MMR190.BB3 (CD206?)&lt;/td&gt;&lt;td align="left"&gt;27&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;20&lt;/td&gt;&lt;td align="left"&gt;70772&lt;/td&gt;&lt;td align="left"&gt;L25&lt;/td&gt;&lt;td align="left"&gt;28&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;21&lt;/td&gt;&lt;td align="left"&gt;Positive Control 1&lt;/td&gt;&lt;td align="left"&gt;CMRF-75&lt;/td&gt;&lt;td align="left"&gt;12&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;22&lt;/td&gt;&lt;td align="left"&gt;Positive Control 2&lt;/td&gt;&lt;td align="left"&gt;CMRF-82&lt;/td&gt;&lt;td align="left"&gt;12&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;23&lt;/td&gt;&lt;td align="left"&gt;Positive Control 3&lt;/td&gt;&lt;td align="left"&gt;CD1a&lt;/td&gt;&lt;td align="left"&gt;31&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;24&lt;/td&gt;&lt;td align="left"&gt;Second Ab&lt;/td&gt;&lt;td align="left"&gt;2nd Ab&lt;/td&gt;&lt;td align="left"&gt;31&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;25&lt;/td&gt;&lt;td align="left"&gt;70875&lt;/td&gt;&lt;td align="left"&gt;AZN-D1 (CD209)&lt;/td&gt;&lt;td align="left"&gt;29&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;26&lt;/td&gt;&lt;td align="left"&gt;70876&lt;/td&gt;&lt;td align="left"&gt;AZN-D2 (CD209)&lt;/td&gt;&lt;td align="left"&gt;29&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;27&lt;/td&gt;&lt;td align="left"&gt;70874&lt;/td&gt;&lt;td align="left"&gt;MMRI-4 (CD205)&lt;/td&gt;&lt;td align="left"&gt;12,25&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>14807</offset><text>Sample	Panel number	Monoclonal antibody (CD*)	Reference	 	1	70011	BG6	12	 	2	70194	HP-Fl(CD85i)ILT2	13	 	3	70293	BU10	14	 	4	70345	7H5 (CD85a) ILT5	15	 	5	70346	42D1 (CD85f)ILT4	16	 	6	70358	ZM3.8 (CD85j) ILT3	17	 	7	70427	DCGM-4 (CD207) Langerin	18	 	8	70435	DC-LAMP (CD208)	19	 	9	70451	TPD153	20	 	10	70511	RFD-1	21	 	11	70512	RFD-7	22	 	12	70375	CMRF-44	7	 	13	70376	CMRF-56	23	 	14	70802	MR15-2 (CD206)	24	 	15	70808	DEC-205 (CD205)	6,12,25	 	16	70807	CDlb/c	31	 	17	70806	55K-2 fascin	26	 	18	70776	MMR1.16 (CD206)	27	 	19	70767	MMR190.BB3 (CD206?)	27	 	20	70772	L25	28	 	21	Positive Control 1	CMRF-75	12	 	22	Positive Control 2	CMRF-82	12	 	23	Positive Control 3	CD1a	31	 	24	Second Ab	2nd Ab	31	 	25	70875	AZN-D1 (CD209)	29	 	26	70876	AZN-D2 (CD209)	29	 	27	70874	MMRI-4 (CD205)	12,25	 	</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>15603</offset><text>(CD*): Hart DNJ., Clark GJ. MacDonald K., Kato M., Vuckovic S., Lopez A., Wykes M., Munster D.. 7th Leucocyte Differentiation antigen workshop, DC section summary. D. Mason, Editor, Leukocyte Typing VII, Oxford University Press. Oxford. In Press 2001 </text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>15855</offset><text>Cell culture</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>15868</offset><text>Adherent PBMC were obtained from a normal healthy donor and cultured in 25-cm2 tissue culture flasks, with complete medium for DC culture {Complete Medium: RPMI 1640 with 25 mM Hepes buffer with L-glutamine (Gifco BRL, Basel Switzerland), supplemented with 10% heat-inactivated FBS, and 1 ml of Antibiotic/Antimicotic (Gifco BRL)} and supplemented with rhGM-CSF (250 ng/ml) +rhIL-4 (100 ng/ml) in order to generate Dermal DC like (Mo-DC). Adherent PBMC were also cultured in 25-cm2 tissue culture flasks, with rhGM-CSF (250 ng/ml) +rhIL-4 (100 ng/ml) and rhTGF-pl (10 ng/ml) in order to generate DC like Langerhans cell (Mo-LC). Afterwards, the DC (Mo-DC and Mo-LC) cultures were incubated at 37&#176;C, 5% CO2 for 7, 14, 21 and 28 days. Every week, half volume of the medium was removed and replaced with fresh medium without adding additional cytokines.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>16720</offset><text>The Mo-DC and Mo-LC populations were harvested and evaluated at 7, 14, 21 and 28 days</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>16806</offset><text>Flow cytometry analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>16830</offset><text>Cells (105 cells/l00 ul) were incubated with 10 &#956;l of mAb on ice for 30'. Cells were washed, twice with wash buffer (Becton Dickinson, San Jose Ca), and stained with 10 &#956;l (1:100 antibody dilution) anti-mouse Ig FITC-labeled on ice for 30', washed once and fixed with Cellfix&#8482; (Becton Dickinson, San Jose Ca). Thereafter, cells were acquired (104 cells per sample) and analyzed on a FACSCalibur (Becton Dickinson, San Jose Ca). Cells were acquired and gated by FSC and SSC. The gated cells were analyzed by (i) histograms displaying the fluorescent reactivity collected in fluorescence 1 (green channel); (ii) Density plots displaying the fluorescent reactivity collected in fluorescence 1 (green channel) against the FSC. Flow cytometry measurement on non-stained or stained only with the second antibody (secondary antibody) were performed and used as control populations. Secondary antibody only stained cells at day 7 served to determine the markers and the quadrant borders. At least 99% of these cells were located in the lower left quadrant (negative). Three independent experiments were performed. Data were analyzed with CellQuest (Becton Dickinson, San Jose Ca). Statistical analysis (mean, standard deviation and graphics) was performed with Microsoft Excel.</text></passage><passage><infon key="fpage">271</infon><infon key="lpage">296</infon><infon key="name_0">surname:Steinman;given-names:RM</infon><infon key="pub-id_doi">10.1146/annurev.iy.09.040191.001415</infon><infon key="pub-id_pmid">1910679</infon><infon key="section_type">REF</infon><infon key="source">Annu Rev Immunol</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">1991</infon><offset>18104</offset><text>The dendritic cell system and its role in immunogenicity.</text></passage><passage><infon key="fpage">96s</infon><infon key="lpage">98s</infon><infon key="name_0">surname:Katz;given-names:SI</infon><infon key="name_1">surname:Cooper;given-names:KD</infon><infon key="name_2">surname:Iijima;given-names:M</infon><infon key="name_3">surname:Tsuchida;given-names:T</infon><infon key="pub-id_pmid">3874249</infon><infon key="section_type">REF</infon><infon key="source">J Invest Dermatol</infon><infon key="type">ref</infon><infon key="volume">85</infon><infon key="year">1985</infon><offset>18162</offset><text>The role of Langerhans cells in antigen presentation.</text></passage><passage><infon key="fpage">10</infon><infon key="lpage">16</infon><infon key="name_0">surname:Cella;given-names:M</infon><infon key="name_1">surname:Sallusto;given-names:F</infon><infon key="name_2">surname:Lanzavecchia;given-names:A</infon><infon key="pub-id_doi">10.1016/S0952-7915(97)80153-7</infon><infon key="pub-id_pmid">9039784</infon><infon key="section_type">REF</infon><infon key="source">Curr Opin Immunol</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">1997</infon><offset>18216</offset><text>Origin, maturation and antigen presenting function of dendritic cells.</text></passage><passage><infon key="fpage">245</infon><infon key="lpage">252</infon><infon key="name_0">surname:Banchereau;given-names:J</infon><infon key="name_1">surname:Steinman;given-names:RM</infon><infon key="pub-id_doi">10.1038/32588</infon><infon key="pub-id_pmid">9521319</infon><infon key="section_type">REF</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="volume">392</infon><infon key="year">1998</infon><offset>18287</offset><text>Dendritic cells and the control of immunity.</text></passage><passage><infon key="fpage">121</infon><infon key="lpage">135</infon><infon key="name_0">surname:Bender;given-names:A</infon><infon key="name_1">surname:Sapp;given-names:M</infon><infon key="name_2">surname:Schuler;given-names:G</infon><infon key="name_3">surname:Steinman;given-names:RM</infon><infon key="name_4">surname:Bhardwaj;given-names:N</infon><infon key="pub-id_doi">10.1016/0022-1759(96)00079-8</infon><infon key="pub-id_pmid">8841451</infon><infon key="section_type">REF</infon><infon key="source">J Immunol Methods</infon><infon key="type">ref</infon><infon key="volume">196</infon><infon key="year">1996</infon><offset>18332</offset><text>Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood.</text></passage><passage><infon key="fpage">151</infon><infon key="lpage">155</infon><infon key="name_0">surname:Jiang;given-names:W</infon><infon key="name_1">surname:Swiggard;given-names:WJ</infon><infon key="name_2">surname:Heufler;given-names:C</infon><infon key="name_3">surname:Peng;given-names:M</infon><infon key="name_4">surname:Mirza;given-names:A</infon><infon key="name_5">surname:Steinman;given-names:RM</infon><infon key="name_6">surname:Nussenzweig;given-names:MC</infon><infon key="pub-id_doi">10.1038/375151a0</infon><infon key="pub-id_pmid">7753172</infon><infon key="section_type">REF</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="volume">375</infon><infon key="year">1995</infon><offset>18437</offset><text>The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing.</text></passage><passage><infon key="fpage">573</infon><infon key="lpage">581</infon><infon key="name_0">surname:Hock;given-names:BD</infon><infon key="name_1">surname:Starling;given-names:GC</infon><infon key="name_2">surname:Daniel;given-names:PB</infon><infon key="name_3">surname:Hart;given-names:DN</infon><infon key="pub-id_pmid">7875738</infon><infon key="section_type">REF</infon><infon key="source">Immunology</infon><infon key="type">ref</infon><infon key="volume">83</infon><infon key="year">1994</infon><offset>18550</offset><text>Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells.</text></passage><passage><infon key="fpage">1109</infon><infon key="lpage">1118</infon><infon key="name_0">surname:Sallusto;given-names:F</infon><infon key="name_1">surname:Lanzavecchia;given-names:A</infon><infon key="pub-id_pmid">8145033</infon><infon key="section_type">REF</infon><infon key="source">J Exp Med</infon><infon key="type">ref</infon><infon key="volume">179</infon><infon key="year">1994</infon><offset>18723</offset><text>Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.</text></passage><passage><infon key="fpage">961</infon><infon key="lpage">966</infon><infon key="name_0">surname:Geissmann;given-names:F</infon><infon key="name_1">surname:Prost;given-names:C</infon><infon key="name_2">surname:Monnet;given-names:JP</infon><infon key="name_3">surname:Dy;given-names:M</infon><infon key="name_4">surname:Brousse;given-names:N</infon><infon key="name_5">surname:Hermine;given-names:O</infon><infon key="pub-id_doi">10.1084/jem.187.6.961</infon><infon key="pub-id_pmid">9500798</infon><infon key="section_type">REF</infon><infon key="source">J Exp Med</infon><infon key="type">ref</infon><infon key="volume">187</infon><infon key="year">1998</infon><offset>18934</offset><text>Transforming growth factor betal, in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells.</text></passage><passage><infon key="name_0">surname:Nunez;given-names:R</infon><infon key="name_1">surname:Filgueira;given-names:L</infon><infon key="section_type">REF</infon><infon key="source">Oxford</infon><infon key="type">ref</infon><infon key="year">2001</infon><offset>19148</offset><text>Flow cytometry assessment of monoclonal antibody (mAb) reactivities against Dendritic cells (DC) In, D. Mason, Editor, Leukocyte Typing VII, Oxford University Press.</text></passage><passage><infon key="name_0">surname:Nunez;given-names:R</infon><infon key="name_1">surname:Filgueira;given-names:L</infon><infon key="name_2">surname:Nunez;given-names:C</infon><infon key="section_type">REF</infon><infon key="source">Mason D., Editor, Leukocyte Typing VII. Oxford: Oxford University Press.</infon><infon key="type">ref</infon><infon key="year">2001</infon><offset>19314</offset><text>Flow cytometric assessment on human dendritic cell lines (HDCL) of monoclonal antibody (mAb) reactivities and determination of surface antigen expression by cytokine modulation.</text></passage><passage><infon key="name_0">surname:Hart;given-names:DNJ</infon><infon key="name_1">surname:dark;given-names:GJ</infon><infon key="name_2">surname:MacDonald;given-names:K</infon><infon key="name_3">surname:Kato;given-names:M</infon><infon key="name_4">surname:Vuckovic;given-names:S</infon><infon key="name_5">surname:Lopez;given-names:A</infon><infon key="name_6">surname:Wykes;given-names:M</infon><infon key="name_7">surname:Munster;given-names:D</infon><infon key="section_type">REF</infon><infon key="source">Oxford</infon><infon key="type">ref</infon><infon key="year">2001</infon><offset>19492</offset><text>7th Leucocyte Differentiation antigen workshop, DC section summary. D. Mason, Editor, Leukocyte Typing VII, Oxford University Press.</text></passage><passage><infon key="fpage">1809</infon><infon key="lpage">1818</infon><infon key="name_0">surname:Colonna;given-names:M</infon><infon key="name_1">surname:Navarro;given-names:F</infon><infon key="name_2">surname:Bellon;given-names:T</infon><infon key="name_3">surname:Llano;given-names:M</infon><infon key="name_4">surname:Garcia;given-names:P</infon><infon key="name_5">surname:Samaridis;given-names:J</infon><infon key="name_6">surname:Angman;given-names:L</infon><infon key="name_7">surname:Cella;given-names:M</infon><infon key="name_8">surname:Lopez-Botet;given-names:M</infon><infon key="pub-id_doi">10.1084/jem.186.11.1809</infon><infon key="pub-id_pmid">9382880</infon><infon key="section_type">REF</infon><infon key="source">J Exp Med</infon><infon key="type">ref</infon><infon key="volume">186</infon><infon key="year">1997</infon><offset>19625</offset><text>A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells.</text></passage><passage><infon key="fpage">49</infon><infon key="lpage">54</infon><infon key="name_0">surname:Bosseloir;given-names:A</infon><infon key="name_1">surname:Heinen;given-names:E</infon><infon key="name_2">surname:Defrance;given-names:T</infon><infon key="name_3">surname:Bouzhazha;given-names:F</infon><infon key="name_4">surname:Antoine;given-names:N</infon><infon key="name_5">surname:Simar;given-names:LJ</infon><infon key="pub-id_doi">10.1016/0165-2478(94)90034-5</infon><infon key="pub-id_pmid">7829129</infon><infon key="section_type">REF</infon><infon key="source">Immunol Lett</infon><infon key="type">ref</infon><infon key="volume">42</infon><infon key="year">1994</infon><offset>19753</offset><text>Moabs MAS516 and 5B5, two fibroblast markers, recognize human follicular dendritic cells.</text></passage><passage><infon key="fpage">961</infon><infon key="lpage">970</infon><infon key="name_0">surname:Lane;given-names:RD</infon><infon key="name_1">surname:Hegazy;given-names:MG</infon><infon key="name_2">surname:Reimann;given-names:EM</infon><infon key="pub-id_pmid">2476990</infon><infon key="section_type">REF</infon><infon key="source">Biochem Int</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">1989</infon><offset>19843</offset><text>Subcellular localization of glycogen synthase with monoclonal antibodies.</text></passage><passage><infon key="fpage">697</infon><infon key="lpage">704</infon><infon key="name_0">surname:Colonna;given-names:M</infon><infon key="name_1">surname:Samaridis;given-names:J</infon><infon key="name_2">surname:Angman;given-names:L</infon><infon key="pub-id_doi">10.1002/1521-4141(200002)30:2&lt;697::AID-IMMU697&gt;3.3.CO;2-D</infon><infon key="pub-id_pmid">10671229</infon><infon key="section_type">REF</infon><infon key="source">Eur J Immunol</infon><infon key="type">ref</infon><infon key="volume">30</infon><infon key="year">2000</infon><offset>19917</offset><text>Molecular characterization of two novel C-type lectin-like receptors, one of which is selectively expressed in human dendritic cells.</text></passage><passage><infon key="fpage">1743</infon><infon key="lpage">1751</infon><infon key="name_0">surname:Cella;given-names:M</infon><infon key="name_1">surname:Dohring;given-names:C</infon><infon key="name_2">surname:Samaridis;given-names:J</infon><infon key="name_3">surname:Dessing;given-names:M</infon><infon key="name_4">surname:Brockhaus;given-names:M</infon><infon key="name_5">surname:Lanzavecchia;given-names:A</infon><infon key="name_6">surname:Colonna;given-names:M</infon><infon key="pub-id_doi">10.1084/jem.185.10.1743</infon><infon key="pub-id_pmid">9151699</infon><infon key="section_type">REF</infon><infon key="source">J Exp Med</infon><infon key="type">ref</infon><infon key="volume">185</infon><infon key="year">1997</infon><offset>20051</offset><text>A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing.</text></passage><passage><infon key="fpage">2695</infon><infon key="lpage">2704</infon><infon key="name_0">surname:Valladeau;given-names:J</infon><infon key="name_1">surname:Duvert-Frances;given-names:V</infon><infon key="name_10">surname:Davoust;given-names:J</infon><infon key="name_11">surname:Saeland;given-names:S</infon><infon key="name_2">surname:Pin;given-names:JJ</infon><infon key="name_3">surname:Dezutter-Dambuyant;given-names:C</infon><infon key="name_4">surname:Vincent;given-names:C</infon><infon key="name_5">surname:Massacrier;given-names:C</infon><infon key="name_6">surname:Vincent;given-names:J</infon><infon key="name_7">surname:Yoneda;given-names:K</infon><infon key="name_8">surname:Banchereau;given-names:J</infon><infon key="name_9">surname:Caux;given-names:C</infon><infon key="pub-id_doi">10.1002/(SICI)1521-4141(199909)29:09&lt;2695::AID-IMMU2695&gt;3.3.CO;2-H</infon><infon key="pub-id_pmid">10508244</infon><infon key="section_type">REF</infon><infon key="source">Eur J Immunol</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">1999</infon><offset>20175</offset><text>The monoclonal antibody DCGM4 recognizes Langerin, a protein specific of Langerhans cells, and is rapidly internalized from the cell surface.</text></passage><passage><infon key="fpage">325</infon><infon key="lpage">336</infon><infon key="name_0">surname:de Saint-Vis;given-names:B</infon><infon key="name_1">surname:Vincent;given-names:J</infon><infon key="name_10">surname:Davoust;given-names:J</infon><infon key="name_11">surname:Caux;given-names:C</infon><infon key="name_12">surname:Lebecque;given-names:S</infon><infon key="name_2">surname:Vandenabeele;given-names:S</infon><infon key="name_3">surname:Vanbervliet;given-names:B</infon><infon key="name_4">surname:Pin;given-names:JJ</infon><infon key="name_5">surname:Ait-Yahia;given-names:S</infon><infon key="name_6">surname:Patel;given-names:S</infon><infon key="name_7">surname:Mattei;given-names:MG</infon><infon key="name_8">surname:Banchereau;given-names:J</infon><infon key="name_9">surname:Zurawski;given-names:S</infon><infon key="pub-id_pmid">9768752</infon><infon key="section_type">REF</infon><infon key="source">Immunity</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">1998</infon><offset>20317</offset><text>A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment.</text></passage><passage><infon key="fpage">262</infon><infon key="lpage">271</infon><infon key="name_0">surname:Pulford;given-names:K</infon><infon key="name_1">surname:Jones;given-names:M</infon><infon key="name_2">surname:Banham;given-names:AH</infon><infon key="name_3">surname:Haralambieva;given-names:E</infon><infon key="name_4">surname:Mason;given-names:DY</infon><infon key="pub-id_doi">10.1046/j.1365-2567.1999.00677.x</infon><infon key="pub-id_pmid">10233704</infon><infon key="section_type">REF</infon><infon key="source">Immunology</infon><infon key="type">ref</infon><infon key="volume">96</infon><infon key="year">1999</infon><offset>20459</offset><text>Lymphocyte-specific protein 1: a specific marker of human leucocytes.</text></passage><passage><infon key="fpage">705</infon><infon key="lpage">715</infon><infon key="name_0">surname:Mishra;given-names:BB</infon><infon key="name_1">surname:Poulter;given-names:LW</infon><infon key="name_2">surname:Janossy;given-names:G</infon><infon key="name_3">surname:James;given-names:DG</infon><infon key="pub-id_pmid">6360446</infon><infon key="section_type">REF</infon><infon key="source">Clin Exp Immunol</infon><infon key="type">ref</infon><infon key="volume">54</infon><infon key="year">1983</infon><offset>20529</offset><text>The distribution of lymphoid and macrophage like cell subsets of sarcoid and Kveim granulomata: possible mechanism ofnegative PPD reaction in sarcoidosis.</text></passage><passage><infon key="fpage">187</infon><infon key="lpage">194</infon><infon key="name_0">surname:Roholl;given-names:PJ</infon><infon key="name_1">surname:Kleyne;given-names:J</infon><infon key="name_2">surname:Prins;given-names:ME</infon><infon key="name_3">surname:Hooijkaas;given-names:H</infon><infon key="name_4">surname:Vroom;given-names:TM</infon><infon key="name_5">surname:Van Unnik;given-names:JA</infon><infon key="pub-id_pmid">3341278</infon><infon key="section_type">REF</infon><infon key="source">Am J Clin Pathol</infon><infon key="type">ref</infon><infon key="volume">89</infon><infon key="year">1988</infon><offset>20684</offset><text>Immunologic marker analysis of normal and malignant histiocytes. A comparative study of monoclonal antibodies for diagnostic purposes.</text></passage><passage><infon key="fpage">320</infon><infon key="lpage">334</infon><infon key="name_0">surname:Hock;given-names:BD</infon><infon key="name_1">surname:Feamley;given-names:DB</infon><infon key="name_2">surname:Boyce;given-names:A</infon><infon key="name_3">surname:McLellan;given-names:AD</infon><infon key="name_4">surname:Sorg;given-names:RV</infon><infon key="name_5">surname:Summers;given-names:KL</infon><infon key="name_6">surname:Hart;given-names:DN</infon><infon key="pub-id_doi">10.1034/j.1399-0039.1999.530402.x</infon><infon key="pub-id_pmid">10323336</infon><infon key="section_type">REF</infon><infon key="source">Tissue Antigens</infon><infon key="type">ref</infon><infon key="volume">53</infon><infon key="year">1999</infon><offset>20819</offset><text>Human dendritic cells express a 95 kDa activation/differentiation antigen defined by CMRF-56.</text></passage><passage><infon key="fpage">718</infon><infon key="lpage">724</infon><infon key="name_0">surname:Barrett-Bergshoeff;given-names:M</infon><infon key="name_1">surname:Noorman;given-names:F</infon><infon key="name_2">surname:Bos;given-names:R</infon><infon key="name_3">surname:Rijken;given-names:DC</infon><infon key="pub-id_pmid">9134649</infon><infon key="section_type">REF</infon><infon key="source">Thromb Haemost</infon><infon key="type">ref</infon><infon key="volume">77</infon><infon key="year">1997</infon><offset>20913</offset><text>Monoclonal antibodies against the human mannose receptor that inhibit the binding of tissue-type plasminogen activator.</text></passage><passage><infon key="fpage">1511</infon><infon key="lpage">1519</infon><infon key="name_0">surname:Kato;given-names:M</infon><infon key="name_1">surname:Neil;given-names:TK</infon><infon key="name_2">surname:Feamley;given-names:DB</infon><infon key="name_3">surname:McLellan;given-names:AD</infon><infon key="name_4">surname:Vuckovic;given-names:S</infon><infon key="name_5">surname:Hart;given-names:DN</infon><infon key="pub-id_doi">10.1093/intimm/12.11.1511</infon><infon key="pub-id_pmid">11058570</infon><infon key="section_type">REF</infon><infon key="source">Int Immunol</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2000</infon><offset>21033</offset><text>Expression of multilectin receptors and comparative FITC-dextran uptake by human dendritic cells.</text></passage><passage><infon key="fpage">83</infon><infon key="lpage">188</infon><infon key="name_0">surname:Hu;given-names:W</infon><infon key="name_1">surname:McCrea;given-names:PD</infon><infon key="name_2">surname:Deavers;given-names:M</infon><infon key="name_3">surname:Kavanagh;given-names:JJ</infon><infon key="name_4">surname:Kudelka;given-names:AP</infon><infon key="name_5">surname:Verschraegen;given-names:CF</infon><infon key="pub-id_doi">10.1023/A:1026596609969</infon><infon key="pub-id_pmid">11206843</infon><infon key="section_type">REF</infon><infon key="source">Clin Exp Metastasis</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2000</infon><offset>21131</offset><text>Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors.</text></passage><passage><infon key="fpage">389</infon><infon key="lpage">400</infon><infon key="name_0">surname:Sallusto;given-names:F</infon><infon key="name_1">surname:Cella;given-names:M</infon><infon key="name_2">surname:Danieli;given-names:C</infon><infon key="name_3">surname:Lanzavecchia;given-names:A</infon><infon key="pub-id_pmid">7629501</infon><infon key="section_type">REF</infon><infon key="source">J Exp Med</infon><infon key="type">ref</infon><infon key="volume">182</infon><infon key="year">1995</infon><offset>21289</offset><text>Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.</text></passage><passage><infon key="fpage">1510</infon><infon key="lpage">1514</infon><infon key="name_0">surname:Clayberger;given-names:C</infon><infon key="name_1">surname:Krensky;given-names:AM</infon><infon key="name_2">surname:McIntyre;given-names:BW</infon><infon key="name_3">surname:Koller;given-names:TD</infon><infon key="name_4">surname:Parham;given-names:P</infon><infon key="name_5">surname:Brodsky;given-names:F</infon><infon key="name_6">surname:Linn;given-names:DJ</infon><infon key="name_7">surname:Evans;given-names:EL</infon><infon key="pub-id_pmid">3492556</infon><infon key="section_type">REF</infon><infon key="source">J Immunol</infon><infon key="type">ref</infon><infon key="volume">138</infon><infon key="year">1987</infon><offset>21495</offset><text>Identification and characterization of two novel lymphocyte function-associated antigens, L24 and L25.</text></passage><passage><infon key="fpage">575</infon><infon key="lpage">585</infon><infon key="name_0">surname:Geijtenbeek;given-names:TB</infon><infon key="name_1">surname:Torensma;given-names:R</infon><infon key="name_2">surname:van Vliet;given-names:SJ</infon><infon key="name_3">surname:van Duijnhoven;given-names:GC</infon><infon key="name_4">surname:Adema;given-names:GJ</infon><infon key="name_5">surname:van Kooyk;given-names:Y</infon><infon key="name_6">surname:Figdor;given-names:CG</infon><infon key="pub-id_pmid">10721994</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">100</infon><infon key="year">2000</infon><offset>21598</offset><text>Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses.</text></passage><passage><infon key="fpage">1803</infon><infon key="lpage">1808</infon><infon key="name_0">surname:Yokoyama;given-names:WM</infon><infon key="pub-id_doi">10.1084/jem.186.11.1803</infon><infon key="pub-id_pmid">9417473</infon><infon key="section_type">REF</infon><infon key="source">J Exp Med</infon><infon key="type">ref</infon><infon key="volume">186</infon><infon key="year">1997</infon><offset>21713</offset><text>What goes up must come down: the emerging spectrum of inhibitory receptors.</text></passage><passage><infon key="fpage">9.17.1</infon><infon key="lpage">9.17.15</infon><infon key="name_0">surname:Nunez;given-names:R</infon><infon key="section_type">REF</infon><infon key="source">New York John Wiley &amp; Sons, Inc</infon><infon key="type">ref</infon><infon key="volume">Supplement 17</infon><infon key="year">2001</infon><offset>21789</offset><text>Assessment of surface markers and functionality of Dendritic cells. Unit 9.17 in Robinson J.P., Darzynkiewicz Z., Dean P., Orfao A., Rabinovitch P., Tanke H., Wheeless L. eds. Current protocols in Cytometry.</text></passage></document></collection>